In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections
Ellie J C Goldstein, Diane M Citron, Yumi A Warren, Kerin L Tyrrell, C Vreni Merriam, Helen T Fernandez, Ellie J C Goldstein, Diane M Citron, Yumi A Warren, Kerin L Tyrrell, C Vreni Merriam, Helen T Fernandez
Abstract
Tests of dalbavancin's in vitro activity against 209 aerobic and 120 anaerobic isolates from pretreatment diabetic foot infections showed an MIC(90) of < or =0.125 microg/ml against methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA), and 120 anaerobes (Clostridium perfringens, other clostridia, Peptoniphilus asaccharolyticus, Finegoldia magna, and Anaerococcus prevotii), compared to respective MIC(90)s for MSSA and MRSA of 0.5 and 1 microg/ml for vancomycin, 4 and 4 microg/ml for linezolid, 0.5 and 0.5 microg/ml for daptomycin, and 0.25 and >8 microg/ml for clindamycin.
References
- Bailey, T. S., H. M. Yu, and E. J. Rayfield. 1985. Patterns of foot examination in a diabetes clinic. Am. J. Med. 78:371-374.
- Diederen, B. M., and J. A. Kluytmans. 2006. The emergence of infections with community-associated methicillin resistant Staphylococcus aureus. J. Infect. 52:157-168.
- Frazee, B. W., J. Lynn, E. D. Charlebois, L. Lambert, D. Lowery, and F. Perdreau-Remington. 2005. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann. Emerg. Med. 45:311-320.
- Goldstein, B. P., G. Candiani, T. M. Arain, G. Romano, I. Ciciliato, M. Berti, M. Abbondi, R. Scotti, M. Mainini, and F. Ripamonti. 1995. Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic. Antimicrob. Agents Chemother. 39:1580-1588.
- Goldstein, E. J. C., D. M. Citron, C. V. Merriam, Y. Warren, K. Tyrrell, and H. T. Fernandez. 2003. In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria. Antimicrob. Agents Chemother. 47:1968-1971.
- Goldstein, E. J. C., D. M. Citron, and C. A. Nesbit. 1996. Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases. Diabetes Care 19:638-641.
- Goldstein, E. J. C., D. M. Citron, Y. A. Warren, K. L. Tyrrell, C. V. Merriam, and H. Fernandez. 2006. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob. Agents Chemother. 50:148-155.
- Hogan, P., T. Dall, and P. Nikolov. 2003. Economic costs of diabetes in the US in 2002. Diabetes Care 26:917-932.
- Jauregui, L. E., S. Babazadeh, E. Seltzer, L. Goldberg, D. Krievins, M. Frederick, D. Krause, I. Satilovs, Z. Endzinas, J. Breaux, and W. O'Riordan. 2005. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. 41:1407-1415.
- Jones, R. N., D. J. Biedenbach, D. M. Johnson, and M. A. Pfaller. 2001. In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. J. Chemother. 13:244-254.
- Jones, R. N., M. S. Stillwell, H. S. Sader, T. R. Fritsche, and B. P. Goldstein. 2006. Spectrum and potency of dalbavancin tested against 3322 gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn. Microbiol. Infect. Dis. 54:149-153.
- Jousimies-Somer, H. R., P. Summanen, D. M. Citron, E. J. Baron, H. M. Wexler, and S. M. Finegold. 2002. Wadsworth-KTL anaerobic bacteriology manual. Star Publishing, Belmont, CA.
- Lin, G., K. Credito, L. M. Ednie, and P. C. Appelbaum. 2005. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob. Agents Chemother. 49:770-772.
- Moran, G. J., R. N. Amii, F. M. Abrahamian, and D. A. Talan. 2005. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg. Infect. Dis. 11:928-930.
- Murray, P. R., E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken (ed.). 2003. Manual of clinical microbiology, 8th ed. ASM Press, Washington, D.C.
- NCCLS. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Document M7-A6. NCCLS, Wayne, Pa.
- NCCLS. 2004. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A6. NCCLS, Wayne, Pa.
- Seltzer, E., M. B. Dorr, B. P. Goldstein, M. Perry, J. A. Dowell, and T. Henkel. 2003. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. 37:1298-1303.
- Streit, J. M., T. R. Fritsche, H. S. Sader, and R. N. Jones. 2004. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn. Microbiol. Infect. Dis. 48:137-143.
Source: PubMed